PFE - Inflation-Busting Price Hikes For Ozempic Mounjaro And Others: Are Drugmakers Profiteering? | Benzinga
Diabetes treatments such as Ozempic and Mounjaro became the blockbuster drugs of 2023 thanks to their popularity as weight-loss remedies. Prices for a month’s supply of these drugs were high then, and in 2024 their manufacturers have raised them higher still.
According to data by 46brooklyn Research, commissioned by the Wall Street Journal, the price for Novo Nordisk‘s (NYSE:NOVO) Ozempic was increased at the start of the year by 3.5% to nearly $970 for a month’s supply.
Meanwhile, the price of a month’s treatment of Eli Lilly‘s (NYSE:LLY) Mounjaro increased by 4.5% to around $1,070, according to the data.
The manufacturers told the WSJ that price increases consider factors such as market conditions and inflation, as well as the drug’s value, efficacy and safety.
Also Read: Fitness In 2024: If You’re Going To ‘Just Do It’ — Do It Together
Nearly 800 Products Up In Price
It would be unfair to single out just two of the headline-making drugs of 2023, as research shows hundreds of brand-name drugs by multiple manufacturers have ...